← Leaderboards
Brett Stewart Carver
Sloan-Kettering Inst Can Research
$12,016,524
Attributed
$13,942,265
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2014–25$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,942,265 · 7
By mechanism
R01$5,801,805 · 2
T32$3,575,232 · 1
U54$2,442,034 · 1
P50$2,123,194 · 3
Top collaborators
- Jan Grimm5 shared
- Thomas Reiner1 shared
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- David B. Solit$21,393,031
- Elisa De Stanchina$4,011,743
- Jan Grimm$17,140,928
- Alexander Drilon$4,847,187
- Sarat Chandarlapaty$10,852,142
Others in their field
Top investigators on “Malignant Neoplasm Of Prostate”
- David Heimbrook · Leidos Biomedical Research, Inc.$255,843,614
- Leonard Freedman · Leidos Biomedical Research, Inc.$63,277,106
- Walter John Curran · Thomas Jefferson University$61,298,085
- Norman Wolmark · Nsabp Foundation, Inc.$54,888,134
- James J. Dignam · University Of Chicago$48,310,409
- Laurence H Baker · University Of Michigan At Ann Arbor$43,366,962
Research focus
Malignant Neoplasm Of ProstateMalignant NeoplasmsTumorAndrogensResistanceResponseSignal TransductionPre-Clinical ModelClinical TrialsGenerationsProstate Cancer ModelProto-Oncogene Proteins C-AktBiologyPre-ClinicalSpecimenPreclinical TrialAndrogen ReceptorMolecularPten GeneMetastatic Prostate CancerPathway InteractionsTargeted TreatmentBaseCombined Modality Therapy
Grant awards (35)
PSMAâs enzymatic activity as new target for Prostate Cancer diagnosis and therapy$734,548
R01 · FY2025 · CA
T32 Urologic Oncology Research Training Grant$360,828
T32 · FY2025 · CA · contact PI
Project 2: Overcoming Microenvironment-Mediated Resistance to AR Pathway Inhibition in High-Risk Prostate Cancer$212,659
P50 · FY2025 · CA · contact PI
PSMAâs enzymatic activity as new target for Prostate Cancer diagnosis and therapy$697,822
R01 · FY2024 · CA
T32 Urologic Oncology Research Training Program$383,552
T32 · FY2024 · CA · contact PI
Project 2: Overcoming Microenvironment-Mediated Resistance to AR Pathway Inhibition in High-Risk Prostate Cancer$280,975
P50 · FY2024 · CA · contact PI
PSMAâs enzymatic activity as new target for Prostate Cancer diagnosis and therapy$719,857
R01 · FY2023 · CA
Project 2: Overcoming Microenvironment-Mediated Resistance to AR Pathway Inhibition in High-Risk Prostate Cancer$371,701
P50 · FY2023 · CA · contact PI
T32 Urologic Oncology Research Training Program$371,627
T32 · FY2023 · CA · contact PI
PSMAâs enzymatic activity as new target for Prostate Cancer diagnosis and therapy$719,857
R01 · FY2022 · CA
Project 2: Overcoming Microenvironment-Mediated Resistance to AR Pathway Inhibition in High-Risk Prostate Cancer$362,142
P50 · FY2022 · CA · contact PI
T32 Urologic Oncology Research Training Program$360,808
T32 · FY2022 · CA · contact PI
PSMAâs enzymatic activity as new target for Prostate Cancer diagnosis and therapy$734,548
R01 · FY2021 · CA
Project 3: Defining the appropriate context for targeting kinase signaling in combination with androgen receptor blockade to enhance therapeutic response in metastatic prostate cancer$455,764
U54 · FY2021 · CA · contact PI
T32 Urologic Oncology Research Training Program$343,500
T32 · FY2021 · CA · contact PI
Core D: Animal Models$66,672
P50 · FY2021 · CA · contact PI
Project 3: Defining the appropriate context for targeting kinase signaling in combination with androgen receptor blockade to enhance therapeutic response in metastatic prostate cancer$487,545
U54 · FY2020 · CA · contact PI
T32 Urologic Oncology Research Training Program$324,205
T32 · FY2020 · CA · contact PI
Core D: Animal Models$161,780
P50 · FY2020 · CA · contact PI
Project 3: Defining the appropriate context for targeting kinase signaling in combination with androgen receptor blockade to enhance therapeutic response in metastatic prostate cancer$456,888
U54 · FY2019 · CA · contact PI
Urologic Oncology Research Training Grant$313,658
T32 · FY2019 · CA · contact PI
Core D: Animal Models$162,636
P50 · FY2019 · CA · contact PI
Defining Response and Resistance to PI3K and AR inhibition in Prostate Cancer$439,351
R01 · FY2018 · CA · contact PI
Urologic Oncology Research Training Grant$302,547
T32 · FY2018 · CA · contact PI
Core D: Animal Models$170,925
P50 · FY2018 · CA · contact PI
Project 3: Defining the appropriate context for targeting kinase signaling in combination with androgen receptor blockade to enhance therapeutic response in metastatic prostate cancer$1,041,837
U54 · FY2017 · CA · contact PI
Defining Response and Resistance to PI3K and AR inhibition in Prostate Cancer$439,351
R01 · FY2017 · CA · contact PI
Urologic Oncology Research Training Grant$292,379
T32 · FY2017 · CA · contact PI
Core D: Animal Models$171,581
P50 · FY2017 · CA · contact PI
Defining Response and Resistance to PI3K and AR inhibition in Prostate Cancer$439,351
R01 · FY2016 · CA · contact PI
Urologic Oncology Research Training Grant$275,994
T32 · FY2016 · CA · contact PI
Core D: Animal Models$162,123
P50 · FY2016 · CA · contact PI
Defining Response and Resistance to PI3K and AR inhibition in Prostate Cancer$439,351
R01 · FY2015 · CA · contact PI
Urologic Oncology Research Training Grant$246,134
T32 · FY2015 · CA · contact PI
Defining Response and Resistance to PI3K and AR inhibition in Prostate Cancer$437,769
R01 · FY2014 · CA · contact PI